Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2017
Price : $35 *
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Feb 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 24 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 22 Dec 2013 New trial record